1-naphthaleneacetic acid

Identification

Summary

1-naphthaleneacetic acid is a drug used to treat digestive problems from excessive fat consumption and functional disorders of the gallbladder and bile ducts.

Generic Name
1-naphthaleneacetic acid
DrugBank Accession Number
DB01750
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 186.2066
Monoisotopic: 186.068079564
Chemical Formula
C12H10O2
Synonyms
  • 1-Naphthylacetic acid
  • NAA
  • naphthalen-1-yl-acetic acid
  • naphthalene-1-acetic acid
  • α-NAA
  • α-naphthaleneacetic acid
External IDs
  • N 10
  • N 40
  • NSC-15772

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatBile duct disordersCombination Product in combination with: 2-(p-Tolyl)ethyl nicotinate (DB16617)••• •••••••••• ••••• ••••••
Used in combination to treatGallbladder disordersCombination Product in combination with: 2-(p-Tolyl)ethyl nicotinate (DB16617)••• •••••••••• ••••• ••••••
Used in combination to treatDigestion disorder caused by fat digestionCombination Product in combination with: 2-(p-Tolyl)ethyl nicotinate (DB16617)••• •••••••••• ••••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
US-phase kinase-associated protein 1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Galle - Donau - Dragees1-naphthaleneacetic acid (75 mg) + 2-(p-Tolyl)ethyl nicotinate (37.5 mg)Tablet, sugar coatedOralPhafag Pharma Research & Trading Gmb H1962-04-06Not applicableAustria flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aromatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Naphthalene / Organic oxide / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
naphthylacetic acid (CHEBI:32918) / Auxins (C13014)
Affected organisms
Not Available

Chemical Identifiers

UNII
33T7G7757C
CAS number
86-87-3
InChI Key
PRPINYUDVPFIRX-UHFFFAOYSA-N
InChI
InChI=1S/C12H10O2/c13-12(14)8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7H,8H2,(H,13,14)
IUPAC Name
2-(naphthalen-1-yl)acetic acid
SMILES
OC(=O)CC1=C2C=CC=CC2=CC=C1

References

General References
Not Available
Human Metabolome Database
HMDB0032708
KEGG Drug
D01558
KEGG Compound
C13014
PubChem Compound
6862
PubChem Substance
46508218
ChemSpider
6601
BindingDB
50022186
ChEBI
32918
ChEMBL
CHEMBL428495
ZINC
ZINC000000391809
PDBe Ligand
NLA
Wikipedia
1-Naphthaleneacetic_acid
PDB Entries
1lrh / 2p1o / 3n8i / 4o1y

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, sugar coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)135 °CPhysProp
water solubility420 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.24SANGSTER (1993)
pKa4.23 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP2.97ALOGPS
logP2.6Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.75Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area37.3 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity53.82 m3·mol-1Chemaxon
Polarizability19.42 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.9524
Caco-2 permeable+0.8528
P-glycoprotein substrateNon-substrate0.7164
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.9621
Renal organic cation transporterNon-inhibitor0.9033
CYP450 2C9 substrateNon-substrate0.7762
CYP450 2D6 substrateNon-substrate0.9272
CYP450 3A4 substrateNon-substrate0.7625
CYP450 1A2 substrateInhibitor0.8636
CYP450 2C9 inhibitorNon-inhibitor0.9729
CYP450 2D6 inhibitorNon-inhibitor0.9392
CYP450 2C19 inhibitorNon-inhibitor0.9576
CYP450 3A4 inhibitorNon-inhibitor0.9677
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9407
Ames testNon AMES toxic0.7795
CarcinogenicityNon-carcinogens0.7404
BiodegradationNot ready biodegradable0.6522
Rat acute toxicity2.2385 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9474
hERG inhibition (predictor II)Non-inhibitor0.9353
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-0900000000-b2d7fccbd30cb458042c
GC-MS Spectrum - EI-BGC-MSsplash10-0006-0900000000-217de62c6bdb645dae35
GC-MS Spectrum - EI-BGC-MSsplash10-0006-1900000000-782f3a027c45e64394b3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000l-0900000000-c4d585f47162553ecfe7
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0900000000-72a291401920aa2031aa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000f-1900000000-6832a8ba5af17b943f5a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0900000000-9286e6a4a7fcd63b77c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-3900000000-366f82d955e8e0bb86dc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0900000000-a9b666d6c1ff68c70484
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-144.7600886
predicted
DarkChem Lite v0.1.0
[M-H]-136.85196
predicted
DeepCCS 1.0 (2019)
[M+H]+139.24751
predicted
DeepCCS 1.0 (2019)
[M+Na]+146.29832
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin-protein transferase activity
Specific Function
Essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcri...
Gene Name
SKP1
Uniprot ID
P63208
Uniprot Name
S-phase kinase-associated protein 1
Molecular Weight
18657.86 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at September 28, 2023 05:40